---
figid: PMC4770749__oncotarget-06-38952-g009
figtitle: BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis
  by suppressing cyclin-A2/Akt/FOXO3a signaling
organisms:
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC4770749
filename: oncotarget-06-38952-g009.jpg
figlink: /pmc/articles/PMC4770749/figure/F9/
number: F9
caption: GOS and VPA co-treatment promotes cyclin A2 degradation via the ubiquitin-proteasome
  pathway, leading to attenuated Akt signaling. Decreased Akt signaling in turn results
  in dephosphorylation of FOXO3a and thereby activation of FOXO3a transcriptional
  activity leading to upregulation of FOXO3a target genes for apoptosis. Furthermore,
  GOS and VPA decrease the ratio of Bcl-2/Bax, resulting in release of cytochrome
  c (Cyto c) and activation of caspase-9. GOS and VPA combination also inhibits the
  expression of survivin. The overall outcome of GOS and VPA co-treatment is the activation
  of both intrinsic and extrinsic apoptotic pathways, leading to robust apoptosis.
  The as-yet-uncharacterized processes for GOS+VPA-induced downregulation of cyclin
  A2 and Bcl-2 are indicated by dotted lines.
papertitle: The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce
  apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling.
reftext: Gao-Xiang Zhao, et al. Oncotarget. 2015 Nov 17;6(36):38952-38966.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9528419
figid_alias: PMC4770749__F9
figtype: Figure
redirect_from: /figures/PMC4770749__F9
ndex: a02fdd30-def0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4770749__oncotarget-06-38952-g009.html
  '@type': Dataset
  description: GOS and VPA co-treatment promotes cyclin A2 degradation via the ubiquitin-proteasome
    pathway, leading to attenuated Akt signaling. Decreased Akt signaling in turn
    results in dephosphorylation of FOXO3a and thereby activation of FOXO3a transcriptional
    activity leading to upregulation of FOXO3a target genes for apoptosis. Furthermore,
    GOS and VPA decrease the ratio of Bcl-2/Bax, resulting in release of cytochrome
    c (Cyto c) and activation of caspase-9. GOS and VPA combination also inhibits
    the expression of survivin. The overall outcome of GOS and VPA co-treatment is
    the activation of both intrinsic and extrinsic apoptotic pathways, leading to
    robust apoptosis. The as-yet-uncharacterized processes for GOS+VPA-induced downregulation
    of cyclin A2 and Bcl-2 are indicated by dotted lines.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FASLG
  - CDK2
  - CCNA2
  - GPR162
  - BCL2
  - AKT1
  - AKT2
  - AKT3
  - BCL2L11
  - FOXO3
  - BAK1
  - BAX
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - FADD
  - Cdk2
  - Pen
  - alphaTub85E
  - Prosalpha2
  - nAChRalpha2
  - Debcl
  - Akt
  - Fs(3)Bak
  - Dronc
  - Decay
  - Parp
  - Fadd
  - faslg
  - cdk2
  - ccna2
  - chmp2a
  - bcl2l11
  - foxo3a
  - baxa
  - casp8
  - birc5a
  - parp14rs2.1
  - fadd
---
